Monday, November 18, 2024
- 10:30AM-12:30PM
-
Abstract Number: 2518
Behçet’s Disease Immune Landscape Exhibits a Universal NF-kB-mediated Hyperactivation Pattern with Cell-specific TNFAIP3 Responses and a Superimposed IFN-regulated Endotype
Vasculitis – Non-ANCA-Associated & Related Disorders Poster III- 10:30AM-12:30PM
-
Abstract Number: 2402
Belimumab Reduces Disease Flares versus Placebo in Adults with Early Active Systemic Lupus Erythematosus: Results of a Large Integrated Analysis
SLE – Diagnosis, Manifestations, & Outcomes Poster III- 10:30AM-12:30PM
-
Abstract Number: 2365
Benefits of Achieving Early versus Late Clinical Response After Treatment with Biologic and Targeted Synthetic DMARDs Among Patients with PsA in the CorEvitas PsA/Spondyloarthritis Registry
SpA Including PsA – Treatment Poster III- 10:30AM-12:30PM
-
Abstract Number: 2348
Bimekizumab Efficacy and Safety Through 4 Years in Moderate to Severe Plaque Psoriasis: Long-Term Results from a Phase 3 Study and Open-Label Extension
SpA Including PsA – Treatment Poster III- 10:30AM-12:30PM
-
Abstract Number: 2352
Bimekizumab Treatment Was Efficacious to 2 Years Regardless of Duration of axSpA Symptoms: Results from Two Phase 3 Studies
SpA Including PsA – Treatment Poster III- 10:30AM-12:30PM
-
Abstract Number: 2368
Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Improvements in Pain and Fatigue: Up to 2-Year Results from Two Phase 3 Studies
SpA Including PsA – Treatment Poster III- 10:30AM-12:30PM
-
Abstract Number: 1794
Biobehavioral Basis and Outcomes of Cognitive Dysfunction in Childhood Systemic Lupus Erythematosus
SLE – Etiology & Pathogenesis Poster- 10:30AM-12:30PM
-
Abstract Number: 2523
Biological Treatment May Be an Option as First Steroid-Sparing Agent in a Subgroup of Young Takayasu Arteritis Patients with Prominent Acute Phase Reactants and Constitutional Symptoms
Vasculitis – Non-ANCA-Associated & Related Disorders Poster III- 10:30AM-12:30PM
-
Abstract Number: 2387
Biomarkers of Lupus Nephritis Are Less Predictive in APOL1 High Risk Genotype Lupus
SLE – Diagnosis, Manifestations, & Outcomes Poster III- 10:30AM-12:30PM
-
Abstract Number: 1806
Bisphenol a Methylation Scores Associate with SLE and ClinicalSubphenotypes
SLE – Etiology & Pathogenesis Poster- 10:30AM-12:30PM
-
Abstract Number: 2420
Blood Transcriptome Analysis Reveals Enhanced B Cell and Complement Cascade Signatures in Patients with Major Neuropsychiatric Systemic Lupus Erythematosus
SLE – Diagnosis, Manifestations, & Outcomes Poster III- 10:30AM-12:30PM
-
Abstract Number: 2509
Bone Marrow Failure in VEXAS Is Associated with the Degree of UBA1b Deficiency
Vasculitis – Non-ANCA-Associated & Related Disorders Poster III